SOURCE: Equity Markets Inc

September 22, 2011 09:00 ET

Global Situation & Resulting Influences - Research Report on ArQule, Inc. and Exelixis, Inc.

MACAU--(Marketwire - Sep 22, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting ArQule, Inc. (NASDAQ: ARQL) and Exelixis, Inc. (NASDAQ: EXEL). Full content and research is available at www.EquityMarketsInc.com/research.php?id=ARQL+EXEL.

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

Equity Markets has reviewed ArQule, Inc. for its current position within the healthcare industry. ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. The full research report on ArQule, Inc. (NASDAQ: ARQL) is available here: www.EquityMarketsInc.com/research.php?id=ARQL.

Equity Markets has reviewed Exelixis, Inc. for its development within the healthcare industry. Exelixis, Inc. (Exelixis) is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. The full research report on Exelixis, Inc. (NASDAQ: EXEL) is available here: www.EquityMarketsInc.com/research.php?id=EXEL.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information